Sign in
CompletedEarly phase 1

Characterization of the Microbiome in Colonized Dystrophic and Junctional Epidermolysis Bullosa Wounds Before and After Use of APR-TD011 ® Spray Solution

Key facts

Who runs it
Northwestern University
Where
Chicago, United StatesSee the site
Trial code
Status
Completed
Phase
Early phase 1
People taking part
15 people enrolled
Started
6 Feb 2023
Ended
31 Mar 2025
Type of study
Interventional
Treatments tested
  • APR-TD011
Record updated
27 April 2025

Who can take part

Age
6 months and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 6 criteriaShow less

Who can take part

  • Patients 6 months of age or above with junctional or dystrophic epidermolysis bullosa
  • Target wound that has been present for at least 3 weeks and is at least 10 cm2
  • Target wound that is colonized with Staphylococcus aureus and/or Pseudomonas aeruginosa

Who cannot take part

  • Patients currently or recently (within past 4 weeks) on topical or systemic antibiotics
  • Do not agree to avoid bathing or topical application at the target starting the night before the visit
  • Do not agree to avoid dilute bleach or vinegar baths, or other antiseptic use, at the target site starting at screening throughout the study

Where in United States

  • Ann & Robert H. Lurie Children's Hospital of ChicagoChicago, United States

About the trial

What the trial wants to find out

In this pilot study, APR-TD011 antimicrobial wound cleansing spray will be given to all enrolled patients with junctional EB (JEB) or dystrophic epidermolysis bullosa (DEB) with Staphylococcus aureus or Pseudomonas aeruginosa culture-positive wounds. The primary aim will be to evaluate the change in skin microbiome (S. aureus, P. aeruginosa, commensal organisms) before, during, after treatment. Subjects who are colonized by S. aureus or pseudomonas will be treated for 8 weeks, will stop the spray and return at 12 weeks (4 weeks without the spray), and then will be able to use the spray as desired in a 6-month period of open-label use, with further feedback collected.

The group in the trial

  • EB participantsTreatment being tested

    Visits will include screening, pre-treatment (week 0), weeks 4 and 8, followed by a visit without use of the APR-TD011 for 4 weeks (week 12) for microbiome assessment off of therapy.

    Treatment: APR-TD011

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
27 April 2025